10-Q: Inspire Medical Swings to Loss Amidst New Product Launch

Inspire Medical Systems reported a net loss in Q2 2025, despite revenue growth, as increased operating expenses and new product transition challenges impacted profitability.

Summary

• Revenue increased by 10.8% to $217.1 million for the three months ended June 30, 2025, compared to $195.9 million in the prior year period.
• The company reported a net loss of $3.6 million for Q2 2025, a significant swing from a net income of $9.8 million in Q2 2024.
• For the six months ended June 30, 2025, revenue grew 16.3% to $418.4 million, but the net loss increased to $0.6 million from $0.2 million in the prior year period.
• Gross margin slightly decreased to 84.0% in Q2 2025 (from 84.8%) and 84.4% in H1 2025 (from 84.8%), partly due to a $2.1 million charge for excess Inspire IV components.
• Selling, General and Administrative (SG&A) expenses surged by 20.8% in Q2 2025 to $159.5 million, driven by increased headcount, compensation, legal fees, and marketing costs.
• Research and Development (R&D) expenses decreased by 9.2% in Q2 2025 to $26.2 million, primarily due to lower ongoing R&D costs for next-gen products, partially offset by higher compensation.
• Cash, cash equivalents, and investments decreased by $105.8 million to $410.7 million as of June 30, 2025, largely due to $75.0 million in share repurchases and inventory build-up.
• Net cash used in operating activities was $4.0 million for the six months ended June 30, 2025, a shift from $8.8 million provided in the prior year period.
• An impairment charge of $4.0 million was recognized on a strategic investment during Q2 2025.
• The company fully launched its next-generation Inspire V system in the U.S. in May 2025.
• Patients and physicians are delaying Inspire therapy until Inspire V is available, and customers are destocking existing Inspire IV inventory, which is expected to impact revenue in the second half of 2025.
• The company is cooperating with a Civil Investigative Demand from the Department of Justice regarding alleged False Claims Act and Anti-Kickback Statute violations.
• Inspire initiated a patent infringement lawsuit against Nyxoah SA and Nyxoah, Inc. on May 30, 2025, concerning their Genio product.

Sentiment

Score: 4

Explanation: While revenue growth remains positive, the swing to a net loss, negative operating cash flow, and significant increase in SG&A expenses indicate a challenging financial quarter. Near-term revenue is expected to be impacted by new product transition delays and inventory destocking. The ongoing DOJ investigation adds a layer of regulatory uncertainty. Although the long-term view on GLP-1 drugs is presented as potentially beneficial, the immediate competitive landscape and operational headwinds suggest a cautious outlook.

Positives

• Achieved continued revenue growth of 10.8% in Q2 2025 and 16.3% in H1 2025, driven by increased market penetration and awareness.
• Successfully launched the next-generation Inspire V system in the U.S. in May 2025, indicating ongoing product innovation.
• Expanded U.S. sales territories to 348 and field clinical representatives to 259, demonstrating continued investment in commercial infrastructure.
• Believes that the increasing use of GLP-1 medications for weight loss could, in the long term, benefit the business by reducing BMI in prospective patients and expanding the pool of eligible candidates for Inspire therapy.
• Successfully dismissed a federal securities law class action lawsuit (City of Hollywood Lawsuit) with prejudice on March 24, 2025.
• A stockholder derivative lawsuit (Hollin Lawsuit) was voluntarily dismissed and administratively closed.

Negatives

• Swung to a net loss of $3.6 million in Q2 2025 from a net income of $9.8 million in Q2 2024.
• Reported an increased net loss of $0.6 million for the six months ended June 30, 2025, compared to $0.2 million in the prior year period.
• Gross margin slightly declined to 84.0% in Q2 2025 and 84.4% in H1 2025, partly due to a $2.1 million charge for excess Inspire IV components.
• Operating expenses, particularly SG&A, increased significantly by 20.8% in Q2 2025, outpacing revenue growth.
• Experienced a $4.0 million impairment charge on a strategic investment in Q2 2025.
• Cash, cash equivalents, and investments decreased by $105.8 million, primarily due to share repurchases and inventory build-up.
• Net cash flow from operating activities turned negative, with $4.0 million used in H1 2025 compared to $8.8 million provided in H1 2024.
• Anticipates that patient and physician delays in adopting Inspire V, along with customer destocking of Inspire IV inventory, will negatively impact consolidated revenue primarily in the second half of 2025.
• Acknowledges that GLP-1 drugs, such as Zepbound, could reduce demand for Inspire therapy if used to treat OSA for indications where Inspire is approved.
• Received a Civil Investigative Demand from the Department of Justice concerning allegations of false claims and Anti-Kickback Statute violations related to product marketing, promotion, and reimbursement practices.

Risks

• Continued history of operating losses and dependency on the Inspire system for revenues.
• Ability to achieve and maintain adequate levels of coverage or reimbursement for Inspire therapy.
• Competition from other companies, technologies, and pharmaceuticals, including GLP-1 drugs for OSA treatment.
• Challenges in expanding indications and developing/commercializing additional products and enhancements.
• Difficulty in forecasting customer demand and managing inventory, leading to potential obsolescence or excess charges.
• Dependence on third-party single-source suppliers, which could lead to supply chain disruptions.
• Risks related to consolidation within the healthcare industry.
• Ability to expand, manage, and maintain the direct sales and marketing organization, especially in international markets.
• Challenges in managing rapid growth effectively.
• Ability to hire and retain senior management and other highly qualified personnel.
• Exposure to product liability and warranty claims.
• Ability to address quality issues that may arise with the Inspire system.
• Challenges in successfully integrating any acquired businesses, products, or technologies.
• Impact of changes in global macroeconomic conditions, including inflation, interest rates, tariffs, and labor costs.
• Potential failure of key information technology systems, processes, or physical facilities.
• Ability to commercialize or obtain regulatory approvals/certifications, or delays in such processes.
• Risks of violating anti-bribery, anti-corruption, and anti-money laundering laws.
• Limitations on the ability to use net operating losses and research and development carryforwards due to ownership changes (e.g., Section 382/383).
• Increasing focus on sustainability and environmental, social, and governance (ESG) initiatives.
• Impact of U.S. Food and Drug Administration (FDA) or other regulatory actions and healthcare reform measures.
• Ability to establish and maintain intellectual property protection for Inspire therapy and system, or avoid claims of infringement.
• Changes in U.S. and foreign tax laws, such as the recently enacted One Big Beautiful Bill Act (OBBBA).
• Fluctuations in quarterly and annual financial results due to seasonality, insurance deductibles, ENT surgeon capacity constraints, new product launch delays, pricing pressure, and media coverage.

Future Outlook

The company anticipates continued patient and physician delays in adopting Inspire therapy until the Inspire V system is fully available at customer locations, and expects customer destocking of Inspire IV inventory to impact consolidated revenue primarily in the second half of 2025. Direct-to-consumer marketing expenditures are projected to increase significantly in the second half of 2025, with plans to enhance and expand digital scheduling capabilities. Research and development expenses are expected to rise due to ongoing development of the SleepSync platform and next-generation products, as well as expanded clinical studies. While acknowledging potential near-term impacts, the company believes GLP-1 drugs could long-term benefit the business by expanding the pool of eligible patients for Inspire therapy. Management believes existing cash and investments will cover operating needs and capital expenditures for at least the next 12 months, but may seek additional capital through equity or debt financings.

Management Comments

• "We expect to continue to see patients delay Inspire therapy until centers meet these criteria and Inspire V is available at their location through the end of 2025."
• "While we cannot quantify the impact at this time or predict if these patterns may change, we anticipate that the occurrence of patients and physicians delaying Inspire therapy and the destocking by some of our customers of their existing Inspire IV inventory may impact our consolidated revenue until Inspire V is fully available at our customer locations and our customers have used their existing Inspire IV inventory, which we expect to primarily occur in the second half of 2025."
• "Moving forward, we plan to refine and optimize our outreach strategies, with an emphasis on expanding digital advertising efforts to reach more qualified patients."
• "We expect our direct-to-consumer expenditures to increase significantly over 2024 levels during the second half of 2025."
• "While we cannot quantify the impact, we believe that some prospective patients are attempting a trial of GLP-1 medication to reduce their BMI and OSA severity prior to considering Inspire therapy."
• "We believe that in the long term there could be a benefit to our business as a result of GLP-1s reducing the BMI of our prospective patients and increasing the overall number of eligible patients for our Inspire therapy, although there can be no assurance of such benefit at this time."
• "We believe our balance sheet and liquidity as of August 4, 2025 provides us with flexibility, and that our cash, cash equivalents, and investments will satisfy our operating needs and capital expenditures for at least the next 12 months."

Industry Context

The medical technology industry for obstructive sleep apnea (OSA) is experiencing evolving competitive dynamics with the rise of pharmaceutical treatments like GLP-1 drugs. Specifically, the FDA approval of Zepbound (tirzepatide) for OSA in patients with obesity introduces a new non-surgical treatment option. Inspire Medical Systems, a leader in neurostimulation for OSA, acknowledges this new competition but also posits a potential long-term benefit, suggesting that GLP-1s could reduce patient BMI, making more individuals eligible for Inspire therapy if they still present with tongue base collapse. This indicates a potential shift in patient pathways, where GLP-1s might serve as a precursor to or complementary treatment for Inspire therapy, rather than a direct replacement for all patients.

Comparison to Industry Standards

• The filing mentions Eli Lilly and Company's SURMOUNT-OSA trial results for tirzepatide, showing a 50.7% reduction in Apnea-Hypopnea Index (AHI) and 43% disease resolution (AHI < 5 or AHI 5-14 with ESS score of 10). This provides a benchmark for pharmaceutical efficacy in OSA treatment.
• Inspire's average patient BMI of 29 is noted, contrasting with American Academy of Sleep Medicine guidelines recommending weight loss prior to surgery for BMI over 35 and non-surgical solutions for BMI over 40, suggesting Inspire targets a specific patient demographic.
• The company initiated a patent infringement lawsuit against Nyxoah SA and Nyxoah, Inc. regarding their Genio product, indicating active defense of its intellectual property against direct competitors in the neurostimulation space.

Legal Proceedings

• A purported federal securities law class action, City of Hollywood Firefighters Pension Fund v. Inspire Medical Systems, Inc., et. al., was dismissed with prejudice on March 24, 2025.
• A stockholder derivative lawsuit, Lawrence Hollin v. Herbert, et al., was voluntarily dismissed and administratively closed on September 5, 2024.
• Received a Civil Investigative Demand (CID) from the Department of Justice U.S. Attorneys Office for the District of Minnesota on January 17, 2025, concerning allegations of false claims, including false claims arising from violations of the Anti-Kickback Statute, submitted to government payors.
• Initiated a legal action against Nyxoah SA and its subsidiary Nyxoah, Inc. on May 30, 2025, in the United States District Court for the District of Delaware, alleging patent infringement by Nyxoah's Genio product and seeking a permanent injunction and monetary damages.

Related Party Transactions

• Entered into a Cost Sharing Agreement in December 2023 with an entity controlled by the Chief Executive Officer to share costs of a corporate suite at a sports and entertainment venue. The company recognized an expense of less than $0.1 million for Q2 2025 and $0.1 million for H1 2025.

Stakeholder Impact

• **Shareholders:** Experienced a swing to net loss and negative operating cash flow, which could impact investor sentiment. Share repurchases reduced outstanding shares but the program is now exhausted. Ongoing legal and regulatory risks (DOJ investigation, patent litigation) introduce uncertainty.
• **Employees:** Benefit from increased headcount and higher compensation, including stock-based compensation. Changes to equity award treatment for retirement-eligible employees were implemented.
• **Customers (Hospitals & ASCs):** Face delays in acquiring and implanting the new Inspire V system due to training and onboarding requirements, and are managing existing Inspire IV inventory, which may affect their operational efficiency and purchasing patterns.
• **Patients:** May experience delays in receiving Inspire therapy due to the Inspire V transition. New pharmaceutical options like GLP-1s could offer alternative or complementary treatment pathways for Obstructive Sleep Apnea.
• **Suppliers:** The company's dependence on single-source suppliers for components of the Inspire system poses a risk of supply disruptions.
• **Creditors:** The company's liquidity position is deemed sufficient for the next 12 months, but potential future capital raises through debt financing could alter the debt profile.

Next Steps

• Refine and optimize outreach strategies, with an emphasis on expanding digital advertising efforts to reach more qualified patients.
• Enhance and expand the digital scheduling capability of the Inspire Advisor Care Program during the remainder of 2025.
• Continue investments in research and development efforts to develop future generations of Inspire systems and support future regulatory submissions for expanded indications and new markets.
• Finalize the assessment and incorporate the complete effects of the One Big Beautiful Bill Act (OBBBA) into financial statements for the period ending September 30, 2025.
• Cooperate with the Department of Justice investigation regarding allegations of false claims and Anti-Kickback Statute violations.

Key Dates

Recommendation

Inspire Medical Systems demonstrates continued revenue growth and innovation with the launch of Inspire V. However, the swing to a net loss, negative operating cash flow, and significant increase in SG&A expenses raise profitability concerns. Near-term revenue is expected to be impacted by the Inspire V transition and customer inventory management. The emergence of GLP-1 drugs as a competitive factor, while potentially expanding the long-term market, introduces immediate uncertainty. The ongoing DOJ investigation adds regulatory risk. For these reasons, a 'Hold' recommendation is appropriate, suggesting existing investors maintain their position while monitoring the company's ability to return to profitability, effectively manage the product transition, and navigate the evolving competitive and regulatory landscape.

Keywords

Obstructive Sleep Apnea, Neurostimulation, Inspire System, Medical Devices, Sleep Apnea Treatment, Hypoglossal Nerve Stimulation, FDA Approval, Healthcare Technology, GLP-1 Drugs, Zepbound, SEC Filing, Quarterly Report, Financial Performance